Abeona Therapeutics (ABEO) Asset Writedowns and Impairment (2022)
Abeona Therapeutics (ABEO) posted quarterly Asset Writedowns and Impairment of -$1.2 million for Q2 2023, down 2887.18% year-over-year from $41798.5 in Q2 2022, and down 1265.0% quarter-over-quarter from $100000.0 in Q1 2023.
Powered by 
Analysis
Abeona Therapeutics (ABEO) Asset Writedowns and Impairment (2022) Analysis & Trends
Abeona Therapeutics' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at -$1.2 million for Q2 2023.
- In Q2 2023, Asset Writedowns and Impairment fell 2887.18% year-over-year to -$1.2 million; the TTM figure through Dec 2023 stood at -$1.1 million (down 176.07% YoY), while the FY2023 annual figure was -$1.1 million, down 176.07% from the prior year.
- Asset Writedowns and Impairment for Q2 2023 stood at -$1.2 million, down from $100000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $1.6 million in Q1 2022, with the low at -$1.2 million in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Abeona Therapeutics | 342.29 Mn | 195.46 Mn | 7.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 711,000.00 |
| Jun 30, 2022 | -1.50 Mn |
| Mar 31, 2022 | 3.30 Mn |